Stemina Biomarker Discovery announced today that its decTOX quickPredict (devTOXqP) screening platform was able to predict with high accuracy developmental toxicity in humans.

The study, which published in the Toxicological Sciences, resulted from an evaluation of 1,065 chemical and drug substances using devTOXqP.

“Through this EPA research, the devTOXqP test demonstrated its potential to detect developmental toxicity across a wide variety of chemicals and pharmaceutical compounds,” Stemina CEO Elizabeth Donley said in a statement.

According to a release, the U.S. EPA’s research suggests that devTOXqP is a useful tool for predicting developmental toxicants in humans and reducing the need for animal testing.